In yesterday’s Wall Street session, Amicus Therapeutics Inc. (NASDAQ:FOLD) shares traded at $13.60, down -0.33% from the previous session.
12 analysts cover Amicus Therapeutics Inc. (NASDAQ:FOLD), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $12.00, we find $16.00. Given the previous closing price of $13.65, this indicates a potential upside of 17.22 percent. FOLD stock price is now 10.72% away from the 50-day moving average and 14.44% away from the 200-day moving average. The market capitalization of the company currently stands at $3.89B.
The stock has received a hold rating from 5 analysts and a buy rating from 7. Brokers who have rated the stock have averaged $15.90 as their price target over the next twelve months.
With the price target of $14, Morgan Stanley recently initiated with Equal-Weight rating for Amicus Therapeutics Inc. (NASDAQ: FOLD).
In other news, Crowley John F, Executive Chairman sold 6,044 shares of the company’s stock on Jul 17. The stock was sold for $81,263 at an average price of $13.45. Upon completion of the transaction, the Executive Chairman now directly owns 938,185 shares in the company, valued at $12.76 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 13, President & CEO Campbell Bradley L sold 6,800 shares of the business’s stock. A total of $85,091 was realized by selling the stock at an average price of $12.51. This leaves the insider owning 806,854 shares of the company worth $10.97 million. Insiders disposed of 1,123,535 shares of company stock worth roughly $15.28 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FOLD stock. A new stake in Amicus Therapeutics Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $30,599,000. GREAT LAKES ADVISORS, LLC invested $7,807,000 in shares of FOLD during the first quarter. In the first quarter, GHOST TREE CAPITAL, LLC acquired a new stake in Amicus Therapeutics Inc. valued at approximately $6,462,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in FOLD for approximately $5,292,000. GREAT POINT PARTNERS I LP purchased a new stake in FOLD valued at around $5,170,000 in the second quarter. In total, there are 320 active investors with 105.77% ownership of the company’s stock.
On Monday morning Amicus Therapeutics Inc. (NASDAQ: FOLD) stock kicked off with the opening price of $13.64. During the past 12 months, Amicus Therapeutics Inc. has had a low of $9.10 and a high of $13.85. As of last week, the company has a debt-to-equity ratio of 3.83, a current ratio of 2.90, and a quick ratio of 2.70. The fifty day moving average price for FOLD is $12.33 and a two-hundred day moving average price translates $11.90 for the stock.
The latest earnings results from Amicus Therapeutics Inc. (NASDAQ: FOLD) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.18, missing analysts’ expectations of -$0.15 by -0.03. This compares to -$0.30 EPS in the same period last year. The net profit margin was -60.60% and return on equity was -153.70% for FOLD. The company reported revenue of $86.27 million for the quarter, compared to $78.72 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 9.6 percent. For the current quarter, analysts expect FOLD to generate $89.87M in revenue.
Amicus Therapeutics Inc.(FOLD) Company Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children’s Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
